Disc Medicine, Inc.
bitopertin
erythropoietic protoporphyria
Resolved
140days ago
Catalyst readout · Feb 17, 2026
What's at stake
A key catalyst for bitopertin (erythropoietic protoporphyria) is expected Feb 17, 2026.
Primary source
· SEC 8-K
verified 16h ago
“On February 17, 2026, Disc Medicine, Inc. (the “Company”) will host a previously-announced conference call at 8:00 AM ET to discuss the Complete Response Letter issued by the U.S. Food and Drug Administration on February 13, 2026”